A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)
Clinical trial NCT01605396 · COMPLETED
Trial details
- NCT number
- NCT01605396
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-07-04
- Primary completion
- 2014-02-19
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.